[Efficacy and safety of omalizumab in patients with refractory allergic asthma: a meta-analysis].

Chen, X Q; Jia, X Y; Wu, J J; Huang, M; Sun, W; Ji, Ningfei

Chen, X Q; Jia, X Y; Wu, J J; Huang, M; Sun, W; Ji, Ningfei.

Afiliação

Chen XQ; Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jia XY; Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Wu JJ; Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Huang M; Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Sun W; Department of Respiratory and Critical Care Medicine, Xishan People's Hospital of Wuxi City, Wuxi 214000, China.
Ji N; Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Zhonghua Yi Xue Za Zhi ; 102(28): 2201-2209, 2022 Jul 26.

Article em Zh | MEDLINE | ID: mdl-35872585

Assuntos

Antiasmáticos; Asma; Omalizumab; Antiasmáticos/efeitos adversos; Asma/tratamento farmacológico; Humanos; Omalizumab/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Omalizumab Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google